Predictive models of immune protection from COVID-19 are urgently needed to identify
correlates of protection to assist in the future deployment of vaccines. To address this, we …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
dramatically expedited global vaccine development efforts 1 , 2 – 3 , most targeting the viral ‘spike’ …

Public T-cell responses, in which T cells bearing identical T-cell receptors (TCRs) are
observed to dominate the response to the same antigenic epitope in multiple individuals, have …

Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing knowledge …

The rapid development of multiple vaccines providing strong protection from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement. …

The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection
and vaccine development. Here, we show a comprehensive profile of antibody, B cell …

The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529),
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …

INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA
vaccines are highly effective at preventing infection and especially severe disease. However, …

Background Several SARS-CoV-2 variants of concern have been identified that partly escape
serum neutralisation elicited by current vaccines. Studies have also shown that vaccines …

The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may
compromise vaccine effectiveness and the ability of antibodies triggered by previous …